Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice
- PMID: 31195972
- PMCID: PMC6567620
- DOI: 10.1186/s12866-019-1494-7
Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice
Abstract
Background: Treatment with the α-glucosidase inhibitor acarbose increases median lifespan by approximately 20% in male mice and 5% in females. This longevity extension differs from dietary restriction based on a number of features, including the relatively small effects on weight and the sex-specificity of the lifespan effect. By inhibiting host digestion, acarbose increases the flux of starch to the lower digestive system, resulting in changes to the gut microbiota and their fermentation products. Given the documented health benefits of short-chain fatty acids (SCFAs), the dominant products of starch fermentation by gut bacteria, this secondary effect of acarbose could contribute to increased longevity in mice. To explore this hypothesis, we compared the fecal microbiome of mice treated with acarbose to control mice at three independent study sites.
Results: Microbial communities and the concentrations of SCFAs in the feces of mice treated with acarbose were notably different from those of control mice. At all three study sites, the bloom of a single bacterial taxon was the most obvious response to acarbose treatment. The blooming populations were classified to the largely uncultured Bacteroidales family Muribaculaceae and were the same taxonomic unit at two of the three sites. Propionate concentrations in feces were consistently elevated in treated mice, while the concentrations of acetate and butyrate reflected a dependence on study site. Across all samples, Muribaculaceae abundance was strongly correlated with propionate and community composition was an important predictor of SCFA concentrations. Cox proportional hazards regression showed that the fecal concentrations of acetate, butyrate, and propionate were, together, predictive of mouse longevity even while controlling for sex, site, and acarbose.
Conclusion: We observed a correlation between fecal SCFAs and lifespan in mice, suggesting a role of the gut microbiota in the longevity-enhancing properties of acarbose. Treatment modulated the taxonomic composition and fermentation products of the gut microbiome, while the site-dependence of the responses illustrate the challenges facing reproducibility and interpretation in microbiome studies. These results motivate future studies exploring manipulation of the gut microbial community and its fermentation products for increased longevity, testing causal roles of SCFAs in the observed effects of acarbose.
Keywords: Acarbose; Candidatus Homeothermaceae; Gut microbiome; Longevity; Muribaculaceae; S24-7; Short-chain fatty acids.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures





Similar articles
-
Muribaculaceae Genomes Assembled from Metagenomes Suggest Genetic Drivers of Differential Response to Acarbose Treatment in Mice.mSphere. 2021 Dec 22;6(6):e0085121. doi: 10.1128/msphere.00851-21. Epub 2021 Dec 1. mSphere. 2021. PMID: 34851167 Free PMC article.
-
The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome.mSphere. 2019 Feb 6;4(1):e00528-18. doi: 10.1128/mSphere.00528-18. mSphere. 2019. PMID: 30728281 Free PMC article.
-
Sustained Dysbiosis and Decreased Fecal Short-Chain Fatty Acids after Traumatic Brain Injury and Impact on Neurologic Outcome.J Neurotrauma. 2021 Sep 15;38(18):2610-2621. doi: 10.1089/neu.2020.7506. Epub 2021 Jun 7. J Neurotrauma. 2021. PMID: 33957773 Free PMC article.
-
Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease.Nutrients. 2023 Oct 21;15(20):4466. doi: 10.3390/nu15204466. Nutrients. 2023. PMID: 37892541 Free PMC article. Review.
-
The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease.Gut Microbes. 2024 Jan-Dec;16(1):2393270. doi: 10.1080/19490976.2024.2393270. Epub 2024 Sep 16. Gut Microbes. 2024. PMID: 39284033 Free PMC article. Review.
Cited by
-
Bovine Lactoferrin Protects Dextran Sulfate Sodium Salt Mice Against Inflammation and Impairment of Colonic Epithelial Barrier by Regulating Gut Microbial Structure and Metabolites.Front Nutr. 2021 Apr 16;8:660598. doi: 10.3389/fnut.2021.660598. eCollection 2021. Front Nutr. 2021. PMID: 33954162 Free PMC article.
-
Stigmasterol attenuates hepatic steatosis in rats by strengthening the intestinal barrier and improving bile acid metabolism.NPJ Sci Food. 2022 Aug 27;6(1):38. doi: 10.1038/s41538-022-00156-0. NPJ Sci Food. 2022. PMID: 36030278 Free PMC article.
-
Rethinking neurodegenerative diseases: neurometabolic concept linking lipid oxidation to diseases in the central nervous system.Neural Regen Res. 2024 Jul 1;19(7):1437-1445. doi: 10.4103/1673-5374.387965. Epub 2023 Nov 8. Neural Regen Res. 2024. PMID: 38051885 Free PMC article.
-
The Role of Ames Dwarfism and Calorie Restriction on Gut Microbiota.J Gerontol A Biol Sci Med Sci. 2020 Jun 18;75(7):e1-e8. doi: 10.1093/gerona/glz236. J Gerontol A Biol Sci Med Sci. 2020. PMID: 31665244 Free PMC article.
-
Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites.Front Endocrinol (Lausanne). 2022 Jul 13;13:905171. doi: 10.3389/fendo.2022.905171. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35909556 Free PMC article. Review.
References
-
- Harrison DE, Strong R, Allison DB, Ames BN, Astle CM, Atamna H, Fernandez E, Flurkey K, Javors MA, Nadon NL, Nelson JF, Pletcher S, Simpkins JW, Smith DL, Wilkinson JE, Miller RA. Acarbose, 17- α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2014;13(2):273–82. - PMC - PubMed
-
- Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, de Magalhães JP, Martinez PA, McCord JM, Miller BF, Müller M, Nelson JF, Ndukum J, Rainger GE, Richardson A, Sabatini DM, Salmon AB, Simpkins JW, Steegenga WT, Nadon NL, Harrison DE. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. Aging Cell. 2016;15(5):872–84. - PMC - PubMed
-
- Harrison DE, Strong R, Alavez S, Astle CM, DiGiovanni J, Fernandez E, Flurkey K, Garratt M, Gelfond JAL, Javors MA, Levi M, Lithgow GJ, Macchiarini F, Nelson JF, Sukoff Rizzo SJ, Slaga TJ, Stearns T, Wilkinson JE, Miller RA. Acarbose improves health and lifespan in aging HET3 mice. Aging Cell. 2019;18(2):12898. - PMC - PubMed
-
- Laube H. Acarbose: An update of its therapeutic use in diabetes treatment. Clin Drug Inv. 2002;22(3):141–56.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases